CoChat

Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes

Open access
Barfeld, Stefan J, East, Phil, Zuber, Verena, Mills, Ian G · 2014 · BMC Medical Genomics

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Tumorigenesis is characterised by changes in transcriptional control. Extensive transcript expression data have been acquired over the last decade and used to classify prostate cancers. Prostate cancer is, however, a heterogeneous multifocal cancer and this poses challenges in identifying robust transcript biomarkers. METHODS: In this study, we have undertaken a meta-analysis of publicly available transcriptomic data spanning datasets and technologies from the last decade and encompassing laser capture microdissected and macrodissected sample sets. RESULTS: We identified a 33 gene signature that can discriminate between benign tissue controls and localised prostate cancers irrespective of detection platform or dissection status. These genes were significantly overexpressed in localised prostate cancer versus benign tissue in at least three datasets within the Oncomine Compendium of Expression Array Data. In addition, they were also overexpressed in a recent exon-array dataset as well a prostate cancer RNA-seq dataset generated as part of the The Cancer Genomics Atlas (TCGA) initiative. Biologically, glycosylation was the single enriched process associated with this 33 gene signature, encompassing four glycosylating enzymes. We went on to evaluate the performance of this signature against three individual markers of prostate cancer, v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) expression, prostate specific antigen (PSA) expression and androgen receptor (AR) expression in an additional independent dataset. Our signature had greater discriminatory power than these markers both for localised cancer and metastatic disease relative to benign tissue, or in the case of metastasis, also localised prostate cancer. CONCLUSION: In conclusion, robust transcript biomarkers are present within datasets assembled over many years and cohorts and our study provides both examples and a strategy for refining and comparing datasets to obtain additional markers as more data are generated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12920-014-0074-9

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Gene signatures capable of discriminating between prostate cancer subgroups and classify metastatic disease. Gene signatures generated using the Varambally dataset and found to be significant discriminators of metastatic disease and primary/localised cancers (Additional file 10: Table S8) when applied to the Tomlins and Rawaswamy datasets were used to cluster samples in these datasets in a heatmap. The gene signatures represented are those capable of characterising samples from at least one progression stage (Fischer’s exact < = 0.05). Gene signatures are rows and samples are columns. The colour coded bar at the base of the heatmap indicates the clinical grouping for each sample as also defined in the key. Metastatic hormone refractory, metastatic hormone naïve and hormone refractory vs. naïve represent prostate cancer cases from the Tomlins dataset, as do PIN (prostatic intraepithelial neoplasia) and primary carcinoma. The other categories (metastatic and primary) are samples from the Rawaswamy dataset and are metastatic and primary cancers from multiple organ sites, not simply the prostate gland. The blue bar graph on the right-hand side of the heatmap depicts the number of genes in each signature which are differentially expressed and contribute to the sample clustering in this analysis. For signature 1 (dist 101.6.1 and Additional file 5: Table S3) this is 1748 genes in total as highlighted and other bars are numbers of genes relative to this. The colour scale represents the mean log2 fold change for differential gene signatures (> = abs log2(2)). Red indicates module induction, green repression. Gene signatures significant in both directions are indicated in yellow. Using the mean module log2 fold change we clustered the samples and modules using hierarchical clustering with euclidean distance as a measure of dissimilarity. Data points that contained both induced and repressed values have been excluded from the clustering.
Figure 1 Gene signatures capable of discriminating between prostate cancer subgroups and classify metastatic disease. Gene signatures generated using the Varambally dataset and found to be significant discriminators of metastatic disease and primary/localised cancers (Additional file 10: Table S8) when applied to the Tomlins and Rawaswamy datasets were used to cluster samples in these datasets in a heatmap. The gene signatures represented are those capable of characterising samples from at least one progression stage (Fischer’s exact < = 0.05). Gene signatures are rows and samples are columns. The colour coded bar at the base of the heatmap indicates the clinical grouping for each sample as also defined in the key. Metastatic hormone refractory, metastatic hormone naïve and hormone refractory vs. naïve represent prostate cancer cases from the Tomlins dataset, as do PIN (prostatic intraepithelial neoplasia) and primary carcinoma. The other categories (metastatic and primary) are samples from the Rawaswamy dataset and are metastatic and primary cancers from multiple organ sites, not simply the prostate gland. The blue bar graph on the right-hand side of the heatmap depicts the number of genes in each signature which are differentially expressed and contribute to the sample clustering in this analysis. For signature 1 (dist 101.6.1 and Additional file 5: Table S3) this is 1748 genes in total as highlighted and other bars are numbers of genes relative to this. The colour scale represents the mean log2 fold change for differential gene signatures (> = abs log2(2)). Red indicates module induction, green repression. Gene signatures significant in both directions are indicated in yellow. Using the mean module log2 fold change we clustered the samples and modules using hierarchical clustering with euclidean distance as a measure of dissimilarity. Data points that contained both induced and repressed values have been excluded from the clustering.CC BY · PubMed Central
Figure 2 Differential expression of a 71-gene signature classifier in a prostate cancer exon-array dataset (Taylor et al. ) and the TCGA RNA-seq dataset for prostate cancer (TCGA-PRAD). The expression values of the 71-gene signature (dist.0.6.34) capable of subclustering localised prostate cancer from other samples in all three interrogated datasets are shown in two independent datasets, A. a prostate cancer exon-array dataset (Taylor et al.) and B. TCGA RNA-seq dataset for prostate cancer (TCGA-PRAD) were used. Values were log2 normalized and the mean of the sample groups (PRIMARY TUMOUR/SOLID TISSUE NORMAL) is shown.
Figure 2 Differential expression of a 71-gene signature classifier in a prostate cancer exon-array dataset (Taylor et al. ) and the TCGA RNA-seq dataset for prostate cancer (TCGA-PRAD). The expression values of the 71-gene signature (dist.0.6.34) capable of subclustering localised prostate cancer from other samples in all three interrogated datasets are shown in two independent datasets, A. a prostate cancer exon-array dataset (Taylor et al.) and B. TCGA RNA-seq dataset for prostate cancer (TCGA-PRAD) were used. Values were log2 normalized and the mean of the sample groups (PRIMARY TUMOUR/SOLID TISSUE NORMAL) is shown.CC BY · PubMed Central
Figure 3 Heatmaps confirming the clustering ability of the 33-gene signature in a prostate cancer exon-array dataset (Taylor et al. ) and the TCGA RNA-seq dataset for prostate cancer (TCGA-PRAD). The 33-gene signature was applied to two independent datasets, A. a prostate cancer exon-array dataset (Taylor et al.), and B. TCGA RNA-seq dataset for prostate cancer (TCGA-PRAD). Expression values were log2 transformed, normalized for high level mean and variance and hierarchically clustered using Euclidian distance. Genes are rows and samples are columns. The colour coded bars indicate expression values and the clinical grouping for each sample as defined in the keys.
Figure 3 Heatmaps confirming the clustering ability of the 33-gene signature in a prostate cancer exon-array dataset (Taylor et al. ) and the TCGA RNA-seq dataset for prostate cancer (TCGA-PRAD). The 33-gene signature was applied to two independent datasets, A. a prostate cancer exon-array dataset (Taylor et al.), and B. TCGA RNA-seq dataset for prostate cancer (TCGA-PRAD). Expression values were log2 transformed, normalized for high level mean and variance and hierarchically clustered using Euclidian distance. Genes are rows and samples are columns. The colour coded bars indicate expression values and the clinical grouping for each sample as defined in the keys.CC BY · PubMed Central
Figure 4 Receiver operating characteristic (ROC) curves for discrimination between localised prostate cancer and benign cases, metastatic and benign cases and metastatic and prostate cancers using a 31-gene signature (row 1), AR (row 2), ERG (row 3) and KLK3 (row 4).
Figure 4 Receiver operating characteristic (ROC) curves for discrimination between localised prostate cancer and benign cases, metastatic and benign cases and metastatic and prostate cancers using a 31-gene signature (row 1), AR (row 2), ERG (row 3) and KLK3 (row 4).CC BY · PubMed Central
Figure 5 Workflow for the identification of robust gene signatures and gene sets for clustering prostate cancer cases. In step 1, we identified all statistically significant differentially expressed Affymetrix array probes in a small dataset consisting of 13 macrodissected clinical samples encompassing localised benign prostatic hyperplasia, localised prostate cancer and metastatic disease (GSE3325). We then generated gene signatures from these based on gene coexpression at varying stringency thresholds. These gene signatures were then applied to two additional datasets, a microdissected dataset (Tomlins et al.) and a multi-tissue site cancer and metastatic dataset (Ramaswamy et al.). A large number of the coexpression gene signatures clustered localised prostate cancers from metastatic disease and prostate metastases from other sample sets. The most compact gene signature able to do so consisted of 71 genes (A) and we assessed its expression pattern in two additional datasets, an exon-array dataset (Taylor et al.) and in a RNA-sequenced dataset (TCGA-PRAD). Few of the genes in the significant coexpression gene signatures were overexpressed genes in localised prostate cancers. In the second phase of the study, we abstracted all of the overexpressed genes and refined this down to a set of 33 genes based on significant overexpression in additional publicly available prostate cancer microarray datasets housed within the Oncomine database (B). These genes also effectively clustered benign versus cancer cases in an exon-array dataset (Taylor et al.) an expression microarray dataset (Grasso et al.) and a RNA-sequenced dataset (TCGA-PRAD) (C and D). In conclusion, it is possible to generate gene classifiers of clinical prostate cancer from a small dataset of macrodissected samples with the capacity to classify larger sequenced and microdissected datasets based on clinical characteristics.
Figure 5 Workflow for the identification of robust gene signatures and gene sets for clustering prostate cancer cases. In step 1, we identified all statistically significant differentially expressed Affymetrix array probes in a small dataset consisting of 13 macrodissected clinical samples encompassing localised benign prostatic hyperplasia, localised prostate cancer and metastatic disease (GSE3325). We then generated gene signatures from these based on gene coexpression at varying stringency thresholds. These gene signatures were then applied to two additional datasets, a microdissected dataset (Tomlins et al.) and a multi-tissue site cancer and metastatic dataset (Ramaswamy et al.). A large number of the coexpression gene signatures clustered localised prostate cancers from metastatic disease and prostate metastases from other sample sets. The most compact gene signature able to do so consisted of 71 genes (A) and we assessed its expression pattern in two additional datasets, an exon-array dataset (Taylor et al.) and in a RNA-sequenced dataset (TCGA-PRAD). Few of the genes in the significant coexpression gene signatures were overexpressed genes in localised prostate cancers. In the second phase of the study, we abstracted all of the overexpressed genes and refined this down to a set of 33 genes based on significant overexpression in additional publicly available prostate cancer microarray datasets housed within the Oncomine database (B). These genes also effectively clustered benign versus cancer cases in an exon-array dataset (Taylor et al.) an expression microarray dataset (Grasso et al.) and a RNA-sequenced dataset (TCGA-PRAD) (C and D). In conclusion, it is possible to generate gene classifiers of clinical prostate cancer from a small dataset of macrodissected samples with the capacity to classify larger sequenced and microdissected datasets based on clinical characteristics.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 56

Metadata

Authors
Barfeld, S. J., East, P., Zuber, V., & Mills, I. G.
Affiliations
Oslo University Hospital (NO)
Corresponding author
  • Barfeld, Stefan J
  • Mills, Ian G
Venue
BMC Medical Genomics
Published
2014-12
Volume
7
Issue
1
Pages
513-513
ISSN
1755-8794 (ISSN-L)
OpenAlex
W2034829050
Cited by
47
References
49
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 7 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 5 · 2015: 3
FWCI
0.74
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medical Genomics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (submittedVersion, other-oa)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Funders
  • Kreftforeningen
  • European Molecular Biology Laboratory
  • Cancer Research UK
  • University of Cambridge
  • Universitetet i Oslo
  • Norges Forskningsråd
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
prostate cancer, gene expression signatures, glycosylation, localized prostate cancer, metastatic prostate cancer, ERG, prostate-specific antigen, androgen receptor, tumor heterogeneity
MeSH terms
Glycosylation, Humans, Male, Neoplasm Proteins, Prostatic Neoplasms, Gene Expression Regulation, Neoplastic, Gene Expression Regulation, Developmental, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. https://app.cochat.ai/papers/10.1186/s12920-014-0074-9
The paper
Barfeld, S. J., East, P., Zuber, V., & Mills, I. G. (2014). Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. BMC Medical Genomics. https://doi.org/10.1186/s12920-014-0074-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.